SPL029

SPL029 is a preclinical-stage small molecule drug being developed for the treatment of depression and other mental health disorders. It is part of a proprietary oral tryptamine series originally developed by Small Pharma Ltd., which was acquired by Cybin in 2023. SPL029 acts as an agonist at the serotonin 2A (5-HT2A) receptor. The compound consists of deuterated tryptamine homologues, a modification intended to enhance metabolic stability and optimize the pharmacokinetic profile for oral administration. By utilizing deuteration, the developer aims to provide a more predictable therapeutic window and improved patient outcomes compared to non-deuterated psychedelic analogues.